Improving prostate cancer risk stratification using machine learning applied to routine PSA testing: a multicenter study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Prostate-specific antigen (PSA) screening reduces mortality but suffers from low specificity, leading to overdiagnosis and unnecessary biopsies. While specialized biomarkers exist, their high cost and limited availability hinder widespread implementation. Machine learning (ML) offers a scalable approach to enhance risk stratification using routinely collected clinical data. Methods We conducted a retrospective, large-scale multicenter study including 4,241 Brazilian men (709 prostate cancer cases; 3,532 controls) derived from a nationwide network spanning 421 clinical settings across 10 Brazilian states. Participants were men referred for prostate evaluation. Controls were defined by negative histopathology or PI-RADS 1–2 multiparametric MRI (diagnostic-evaluation cohort with a mixed reference standard). An interpretable machine learning model (PSA model) integrating total PSA, free-to-total PSA ratio, and age was evaluated on a held-out test set and, for robustness, by leave-one-group-out validation across four geographic groups. Incremental value from PSA density (PSAD), PSA kinetics, and complete blood count markers was also assessed. Results The PSA model significantly outperformed a fixed PSA threshold (≥4.0 ng/mL) on the test set (AUC of 0.73 vs. 0.63, p < 0.001). In the PSA gray zone (4–10 ng/mL), discrimination improved from 0.50 to 0.67. At the training-derived threshold, specificity increased from 0.44 to 0.60 (sensitivity 0.73 vs. 0.83), corresponding to 24% fewer referrals for MRI or biopsy at the cost of six additional missed ISUP ≥2 cancers, a potential benefit requiring prospective confirmation. Notably, the model showed higher detection of aggressive disease, with an AUC of 0.81 for intermediate-to-high-risk tumors (Gleason ≥7). Incorporating PSAD further enhanced performance (AUC 0.78; p=0.003), whereas PSA kinetics and CBC markers provided no significant incremental value. Across the four geographic groups, AUCs ranged from 0.70 to 0.74. Conclusions An interpretable ML model utilizing widely available clinical variables provides a scalable risk stratification tool for men referred for prostate evaluation. By demonstrating consistent discrimination across four geographic groups comprising 10 Brazilian states and hundreds of clinical settings, this framework offers a practical strategy to optimize resource allocation in real-world clinical practice.
Source: Frontiers in Oncology
Authors: Daniella Castro Araújo(Writing – original draft, Writing – review & editing), Bruno Aragão Rocha(Writing – original draft, Writing – review & editing), Felipe Vaz Peres(Writing – original draft, Writing – review & editing), Suzylaine da Silva Lima(Writing – original draft, Writing – review & editing), Laura Rabelo Leite(Writing – original draft, Writing – review & editing), Maria Carolina Tostes Pintão(Writing – original draft, Writing – review & editing), Rejane Cristina dos Santos Silva(Writing – original draft, Writing – review & editing), Otavio Jose Eulalio Pereira(Writing – original draft, Writing – review & editing), João Vicente de Morais Malvezzi(Writing – original draft, Writing – review & editing), Flavia Helena da Silva(Writing – original draft, Writing – review & editing), Flávio Francisco Machado(Writing – original draft, Writing – review & editing), Keity de Moura Pinho(Writing – original draft, Writing – review & editing), Vinicius Moura Ribeiro(Writing – original draft, Writing – review & editing), Marco Aurelio Kohara(Writing – original draft, Writing – review & editing), Pedro Henrique Araújo de Souza
Institutions: Fleury S.A. (Brazil), Instituto Nacional de Câncer - INCA
Language: English
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Keywords: prostate cancer, risk stratification, prostate-specific antigen, PSA screening, machine learning, free-to-total PSA ratio, PSA density, PSA kinetics, overdiagnosis, biopsy reduction, Gleason score, PI-RADS, Brazilian men, interpretable models, clinical decision support, multiparametric MRI
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236604930
